Novartis AG has been garnering significant interest following a series of notable occurrences. Buy signals have been detected in the company's Depositary Receipt stock while Deutsche Bank has lifted its price target on Novartis stock to CHF120 following the success of
ianalumab. Despite confronting some bearish moves upon missing major sales, Novartis’ stock is showing strong momentum, leading to calls for a deeper scrutiny of its financial prospects. The company enjoyed a slew of successes with the approval of the cholesterol treatment
Leqvio by the FDA, positive results from the
Phase III trial of Sjögren’s drug, ianalumab, and potential acquisition of Avidity Biosciences. However, its shares fell 1.41% in the after-hours from Swiss stocks report and GDP growth. Looking at Novartis' financial performance, it outperformed in Q2 earnings, yet, with the departure of the CFO, the stock fell. On a brighter note, a potential 52-week high is projected for the company’s stock. Novartis chalked up a strong growth profile with Morgan Stanley's upgrade. Concerningly, the company has seen a decline in European healthcare stocks due to Trump's tariff threat, undermining the company’s strong Q2 showing. The announcement of a $10 billion stock buyback after strong Q2 performance could offer some respite.
Novartis Stocks News Analytics from Fri, 31 Jan 2025 08:00:00 GMT to Sat, 23 Aug 2025 21:47:07 GMT -
Rating 3
- Innovation 9
- Information 8
- Rumor 1
